Tardive akathisia — onset after prolonged exposure; may be irreversible
Withdrawal akathisia — emerges on dose reduction or discontinuation
Therapeutic Considerations
Treatment hierarchy evidence base
2024 JAMA Network Open network meta-analysis
Most comprehensive comparative evidence to date
Propranolol and mirtazapine among highest-ranked treatments
Vitamin B6 had favorable safety-efficacy profile
2026 Schizophrenia Bulletin network meta-analysis
Confirmed propranolol and serotonergic agents as preferred
Benzodiazepines effective but limited by adverse effect profile
B-CALM mnemonic for treatment agents
Beta-blockers (propranolol)
Clonazepam/benzodiazepines
Anticholinergics (biperiden, benztropine)
cLonidine
Mirtazapine
Antipsychotic switching considerations
Cochrane review 2025: switching evidence for non-responsive schizophrenia
Switching carries risk of psychotic relapse during transition
Cross-titration preferred over abrupt switch
Quetiapine, olanzapine, or clozapine as lower-akathisia targets
Canadian Journal of Psychiatry 2018 guidelines
Systematic assessment with BARS recommended at baseline and follow-up
BARS-guided treatment adjustments
Prevention strategies
Akathisia prevention
Use lowest effective antipsychotic dose
Avoid rapid titration — especially risperidone
Screen iron status before initiating antipsychotic therapy
Prefer SGA agents with 5-HT2A antagonism for vulnerable patients
Prophylactic beta-blocker not routinely recommended
Insufficient evidence for prophylactic use
Targeted treatment preferred once akathisia develops
Patient Discharge Instructions
copy discharge instructions
What is akathisia
Akathisia is a medication side effect causing inner restlessness and the urge to move
It is caused by the medication you are taking, not a worsening of your condition
It is treatable and typically improves with medication adjustment
Common symptoms to expect during recovery
Restlessness and urge to move may take a few days to begin improving
The new medication we gave you should help within 24-48 hours
Do not stop your antipsychotic medication without speaking to your doctor first
Medication instructions
Take the prescribed rescue medication exactly as directed
Propranolol: take with food, do not stop suddenly
Clonazepam: do not drive or operate heavy machinery while taking
Mirtazapine: take at bedtime due to sedation
Do not change your antipsychotic dose on your own
Your psychiatrist will guide dose adjustments
Stopping abruptly can cause withdrawal and worsening symptoms
Activity and diet
Movement can temporarily relieve symptoms — gentle walking is encouraged
Restlessness should not prevent you from resting with treatment
Iron-rich foods if iron deficiency was identified
Red meat, leafy greens, legumes, fortified cereals
Take iron supplements with vitamin C to improve absorption
Reduce caffeine intake — may worsen inner restlessness
Return to emergency department immediately for
Return precautions
Thoughts of harming yourself or others
Worsening agitation that is uncontrollable despite medication
Dizziness, fainting, or very slow heartbeat (if taking propranolol)
Severe drowsiness or confusion
New involuntary movements of the face, tongue, or limbs
Inability to eat, drink, or care for yourself due to restlessness
Follow-up instructions
Scheduled follow-up
Return to your psychiatrist or prescribing physician within 48-72 hours
Bring a list of all your current medications to your follow-up visit
References
Guidelines and key sources
Factor SA, Burkhard PR, Caroff S, et al.
Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture
Lancet Neurology 2019; PMID 31279747
Pringsheim T, Gardner D, Addington D, et al.
The Assessment and Treatment of Antipsychotic-Induced Akathisia
Canadian Journal of Psychiatry 2018; PMID 29685069
Gerolymos C, Barazer R, Yon DK, et al.
Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis
JAMA Network Open 2024; JAMA Network Open 2024.1527
Furukawa Y, Imai K, Takahashi Y, Efthimiou O, Leucht S.
Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis
Schizophrenia Bulletin 2026; PMID 38869177
Thippaiah SM, Fargason RE, Birur B.
Struggling to Find Effective Pharmacologic Options for Akathisia? B-CALM!
Psychopharmacology Bulletin 2021; PMID 34421146
Landmark trials and key studies
Barnes TR.
The Barnes Akathisia Rating Scale — Revisited
Journal of Psychopharmacology 2003; PMID 14870947
Schoretsanitis G, Nikolakopoulou A, Guinart D, Correll CU, Kane JM.
Iron Homeostasis Alterations and Risk for Akathisia in Patients Treated With Antipsychotics
European Neuropsychopharmacology 2020; PMID 32444336
Kalniunas A, Chakrabarti I, Mandalia R, Munjiza J, Pappa S.
The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review
Neuropsychiatric Disease and Treatment 2021; PMID 34887662
Shams-Alizadeh N, Maroufi A, Rahmani K, et al.
Evaluating the Effectiveness of Cyproheptadine on Acute Neuroleptic-Induced Akathisia: A Double-Blind RCT
Journal of Clinical Psychopharmacology 2026; PMID 41670043
Zareifopoulos N, Katsaraki M, Stratos P, et al.
Pathophysiology and Management of Akathisia 70 Years After the Introduction of Chlorpromazine
European Review for Medical and Pharmacological Sciences 2021; PMID 34337722
Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA.
The Clinical Challenges of Akathisia
CNS Spectrums 2015; PMID 26683525
Samara MT, Kottmaier E, Helfer B, et al.
Switching Antipsychotics Versus Continued Current Treatment in People With Non-Responsive Schizophrenia
Cochrane Database of Systematic Reviews 2025
Miller CH, Fleischhacker WW.
Managing Antipsychotic-Induced Acute and Chronic Akathisia
Drug Safety 2000; PMID 10647977
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.